StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note released on Saturday morning. The brokerage issued a hold rating on the stock.

Separately, Cantor Fitzgerald reissued a neutral rating on shares of TherapeuticsMD in a report on Thursday, August 17th.

TherapeuticsMD Stock Up 2.7 %

NASDAQ:TXMD opened at $3.42 on Friday. TherapeuticsMD has a twelve month low of $3.25 and a twelve month high of $7.99. The business has a 50 day moving average price of $3.89 and a two-hundred day moving average price of $3.87.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.17). The company had revenue of $0.44 million during the quarter. TherapeuticsMD had a net margin of 61.23% and a return on equity of 232.35%. On average, research analysts expect that TherapeuticsMD will post -0.75 EPS for the current year.

Institutional Investors Weigh In On TherapeuticsMD

A number of large investors have recently added to or reduced their stakes in the business. State Street Corp raised its stake in TherapeuticsMD by 0.3% in the 1st quarter. State Street Corp now owns 7,259,095 shares of the company’s stock valued at $2,758,000 after acquiring an additional 19,452 shares during the period. Renaissance Technologies LLC increased its position in TherapeuticsMD by 243.5% during the 1st quarter. Renaissance Technologies LLC now owns 3,147,599 shares of the company’s stock worth $1,196,000 after buying an additional 2,231,301 shares during the period. Goldman Sachs Group Inc. increased its position in TherapeuticsMD by 727.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,860,361 shares of the company’s stock worth $1,087,000 after buying an additional 2,514,618 shares during the period. Royal Bank of Canada increased its position in TherapeuticsMD by 688.1% during the 1st quarter. Royal Bank of Canada now owns 788,446 shares of the company’s stock worth $299,000 after buying an additional 688,399 shares during the period. Finally, Clearline Capital LP increased its position in TherapeuticsMD by 8.6% during the 2nd quarter. Clearline Capital LP now owns 455,372 shares of the company’s stock worth $1,876,000 after buying an additional 35,947 shares during the period. Institutional investors own 28.68% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.